Advertisement

Sotorasib for KRAS G12C–Mutated NSCLC: CodeBreaK100 Trial
Posted: 05/10/2022 | By: Chase Doyle

Question 1 of 5

Patients treated with sotorasib, a first-in-class KRAS G12C inhibitor, demonstrated a median progression-free survival of how many months?

Choose 1

A
4.3 months
B
6.3 months
C
8.3 months
D
10.3 months

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage